Please assess the completion status of the following clinical trial:

Trial Title: GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed locally advanced or metastatic solid tumor that is refractory to standard therapy or for which no standard therapy exists~  * Progressed after first-line and second-line therapy (if there is a second-line therapy that has been shown to provide clinical benefit)~    * Must receive standard second-line therapy if second-line therapy has been shown to provide clinical benefit~* Evaluable disease by physical examination, imaging, and/or one of the following:~  * Two rising prostate-specific antigen (PSA) levels ≥ 2 weeks apart, with one obtained during screening (for patients with prostate cancer)~ * Two rising CA-125 levels ≥ 2 weeks apart, with one obtained during screening (for patients with ovarian cancer)~* No CNS cancer, either primary lesions or metastatic disease, as the current malignancy~* No pleural effusions, ascites, or leptomeningeal disease as the only manifestation of the current malignancy~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Granulocyte count ≥ 1,500/μL~* Platelet count ≥ 100,000/μL~* Hemoglobin ≥ 9 g/dL~* Serum bilirubin normal~* Alkaline phosphatase ≤ 1.5 times upper limit of normal (ULN) (≤ 4 times ULN for patients with liver or bone metastases)~* AST and ALT ≤ 1.5 times ULN (≤ 5 times the ULN for patients with liver metastases)~* Serum creatinine ≤ 1.5 mg/dL~* INR \< 1.3~* aPTT ≤ 1.5 times ULN~* Fasting total serum cholesterol ≤ 220 mg/dL (without cholesterol-lowering drugs)~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Able and willing to swallow pills~* No malabsorption syndrome or other condition that would interfere with enteral absorption~* No history of significant atherosclerotic disease, including the following:~  * Coronary artery disease (i.e., myocardial infarction within the past year or unstable angina)~ * Documented carotid atheromas~* No history of congestive heart failure or ventricular arrhythmia requiring medication~* No congenital long QT syndrome~* No baseline QTc intervals \> 0.47 seconds on two of three baseline 12-lead ECGs recorded during the screening period~* No active infection requiring intravenous antibiotics~* No known HIV infection~* No uncontrolled hypocalcemia, hypomagnesemia, or hypokalemia, defined as less than the lower limit of normal for the institution despite adequate electrolyte supplementation~* No history of clinically important liver disease, including cirrhosis or viral or other hepatitis~* No current alcohol abuse~* No significant traumatic injury within the past 3 weeks~* No other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the study results or renders the patient at high risk from treatment complications~PRIOR CONCURRENT THERAPY:~* At least 4 weeks since prior chemotherapy, investigational therapy, radiotherapy, or major surgical procedure and recovered~* No concurrent medications with narrow therapeutic indices that are cytochrome P450 substrates (warfarin sodium \[Coumadin®\])~* No concurrent medications known to prolong the QT interval, including any of the following:~  * Quinidine or other anti-arrhythmic agents~ * Haloperidol, fluoxetine, paroxetine, or sertraline~ * Pentamidine, fluoroquinolone, or macrolide antibiotics~* No concurrent medications that may interfere with the metabolism of GDC-0449 (e.g., ketoconazole)~* No concurrent grapefruit juice

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stage 1: GDC-0449 (150 mg) (Type: EXPERIMENTAL): Participants with any tumor received a single oral dose of GDC-0449 hard gelatin capsules at a dosage of 150 milligram (mg) on Day 1. Beginning on Day 8, participants received once daily doses of GDC-0449 150 mg, orally, continuing until disease progression (deterioration of evaluable lesions and/or tumor-related symptoms defined using Response Evaluation Criteria in Solid Tumors Version 1.0 (RECIST v1.0), maximum benefit, or intolerability.
- Stage 1: GDC-0449 (270 mg) (Type: EXPERIMENTAL): Participants with any tumor received a single oral dose of GDC-0449 hard gelatin capsules at a dosage of 270 mg on Day 1. Beginning on Day 8, participants received once daily doses of GDC-0449 270 mg, orally, continuing until disease progression, maximum benefit, or intolerability.
- Stage 1: GDC-0449 (540 mg) (Type: EXPERIMENTAL): Participants with any tumor received a single oral dose of GDC-0449 hard gelatin capsules at a dosage of 540 mg on Day 1. Beginning on Day 8, participants received once daily doses of GDC-0449 540 mg, orally, continuing until disease progression, maximum benefit, or intolerability.
- Stage 2: BCC [GDC-0449 (150 mg)] (Type: EXPERIMENTAL): Participants with basal cell carcinoma (BCC) received a daily oral dose of GDC-0449 hard gelatin capsules at a dosage of 150 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
- Stage 2: BCC [GDC-0449 (270 mg)] (Type: EXPERIMENTAL): Participants with BCC received a daily oral dose of GDC-0449 hard gelatin capsules at a dosage of 270 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
- Stage 2:Safety Expansion Cohort [GDC-0449 (150 mg)] (Type: EXPERIMENTAL): Participants received a daily oral dose of GDC-0449 hard gelatin capsules at a dosage of 150 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.
- Stage 2: New Formulation [GDC-0449 (150 mg )] (Type: EXPERIMENTAL): Participants received a daily oral dose of GDC-0449 Phase II drug product hard gelatin capsules at a dosage of 150 mg starting on Day 1 and continuing until disease progression, maximum benefit, or intolerability.

Based on this trial design, predict the completion outcome and termination type (if applicable).